Researchers at the Plastic Surgery Hospital of the Chinese Academy of Medical Sciences have identified a specific fibroblast cell state—designated as “Fib_5”—that serves as a primary driver of hypertrophic scar formation. Published in Burns & Trauma in 2026, the study reveals that the transcription factor Yin Yang 1 (YY1) acts as a molecular “brake” on this fibrotic process. By restoring YY1 levels in scar-derived fibroblasts, scientists successfully reduced the expression of collagen and other fibrosis-associated proteins, offering a new potential target for therapeutic intervention in pathological scarring.
What characterizes the “Fib_5” cell state in scarring?
Hypertrophic scars occur when the body’s wound-healing process fails to remodel the extracellular matrix, leading to excessive tissue buildup. According to the study by Yu et al. (2026), this pathology is driven by fibroblast heterogeneity. While total fibroblast abundance typically decreases in scar tissue, the Fib_5 subcluster expands significantly. This specific cell population is defined by high expression of ADAM12, COMP, and POSTN, alongside elevated levels of collagen-producing genes like COL1A1 and FN1. Unlike general fibroblast populations, Fib_5 cells are locked into a persistent, pro-fibrotic state that resists normal remodeling.
Single-cell RNA sequencing (scRNA-seq) has revolutionized dermatological research by allowing scientists to catalog 43,303 individual dermal cells, revealing that not all fibroblasts behave the same way during the healing process.
How does YY1 regulate fibroblast activity?
The study identifies the transcription factor YY1 as a critical regulator of fibroblast plasticity. Researchers found that YY1 expression is naturally suppressed in hypertrophic scar fibroblasts, effectively removing the “brake” on fibrotic activity. Using CUT&Tag assays and Western blotting, the team demonstrated that overexpressing YY1 in scar-derived fibroblasts forced these cells to exit their fibrotic program. This intervention resulted in a measurable reduction of p-AKT and fibrosis-associated proteins, suggesting that YY1 restoration could shift the cellular environment from a pathological state toward a more normalized healing trajectory.
What are the future clinical implications for scar treatment?
Current scar therapies remain limited because they often target general inflammation rather than specific, disease-driving cell states. The discovery of the Fib_5-YY1 axis suggests a shift toward precision medicine in dermatology. According to the researchers, while YY1 is not yet a clinical target, the conserved nature of the Fib_5 population across multiple patient datasets indicates that it could serve as a reliable biomarker for assessing scar severity or treatment efficacy. Future research will focus on determining whether in vivo modulation of these pathways can safely halt or reverse the formation of hypertrophic scars in human patients.
When evaluating new scar therapies, look for evidence that targets specific fibroblast sub-lineages rather than broad immunosuppression, as current trends in regenerative medicine favor cell-state-specific interventions.
Frequently Asked Questions
- What is a hypertrophic scar? It is an abnormal wound-healing outcome characterized by excessive collagen deposition and a failure of the skin to properly remodel after an injury.
- Why is fibroblast heterogeneity important? It explains why some wounds heal normally while others develop thick, persistent scars; different fibroblast “subtypes” have different roles in inflammation and collagen production.
- Is YY1 a treatment for scars? Not yet. YY1 is a transcription factor identified as a regulator of scar formation in laboratory settings; it requires further preclinical testing to ensure safety and efficacy in humans.
- How was this study conducted? Researchers used single-cell RNA sequencing (scRNA-seq) on human tissue samples, validated the results against public datasets, and performed functional experiments like Western blotting to confirm the role of YY1.
Interested in the latest breakthroughs in regenerative medicine? Subscribe to our newsletter for monthly updates on dermatological research and emerging clinical trials.
